Toward Artificial Intelligence-driven Clinical Decision Support Tools in Rheumatology
Clinical Snapshot
PICO Framework
| P — Population | Patients with rheumatic diseases and clinicians practising rheumatology |
| I — Intervention | Artificial intelligence-driven clinical decision support systems (CDSS), including machine-learning-based systems |
| C — Comparator | Knowledge-based (rule-based) CDSS or standard clinical practice without CDSS |
| O — Outcomes | Differential diagnosis accuracy, treatment decision support, prediction of patient outcomes, and clinical utility of CDSS in rheumatology practice |
Bottom Line
This narrative review from a Harvard-affiliated rheumatology and biostatistics team provides a conceptually useful but methodologically limited overview of AI-driven clinical decision support systems (CDSS) in rheumatology. The authors make a clinically relevant distinction between rule-based and machine-learning-based CDSS, arguing the latter are better suited to the diagnostic complexity of rheumatic diseases. However, the absence of a systematic search strategy, formal inclusion criteria, risk of bias assessment, and quantitative synthesis means this paper cannot be considered high-level evidence. It functions as an expert opinion and educational resource rather than an evidence synthesis. The review appropriately acknowledges that most AI-driven CDSS in rheumatology remain in developmental or early validation stages, with prospective clinical outcome data largely absent. For Australian rheumatologists, the key takeaway is one of cautious optimism: AI-driven CDSS may eventually support diagnosis, treatment selection, and outcome prediction, but robust prospective validation, TGA regulatory assessment, and local implementation frameworks are prerequisites before clinical adoption. Clinicians should critically evaluate any CDSS tool for transparency, external validation, and potential for algorithmic bias before integration into practice.
Key Findings
P Value: Not reported at the review level
Effect Size: Not applicable — no quantitative synthesis performed. Individual studies discussed narratively without pooled effect size calculation
Primary Outcome: Narrative synthesis of the current state of AI-driven CDSS in rheumatology, covering applications in differential diagnosis, treatment decision support, and outcome prediction across rheumatic conditions
Nnt Or Sensitivity: Not calculable from this narrative review. Individual CDSS studies cited within the review may report diagnostic accuracy metrics (sensitivity, specificity, AUC) but these are not pooled or systematically summarised in the abstract
Confidence Interval: Not reported — no meta-analytic confidence intervals presented
Clinical Application
Implementation of AI-driven CDSS in rheumatology practice faces significant barriers including: data infrastructure requirements (electronic health record integration), need for local validation before deployment, clinician training and change management, regulatory approval processes, and ongoing monitoring for algorithmic drift and bias. The review highlights that most tools remain in research or early implementation phases rather than being ready for routine clinical deployment. In the Australian context, AI-driven CDSS in rheumatology would require TGA regulatory assessment if classified as a medical device under the Software as a Medical Device (SaMD) framework. The RACGP and Australian Rheumatology Association (ARA) have not yet issued specific guidelines on AI-driven CDSS in rheumatology practice. PBS-listed biologics and targeted synthetic DMARDs (e.g., methotrexate, leflunomide, adalimumab, baricitinib) represent potential targets for CDSS-assisted treatment decision support, particularly for optimising step-therapy pathways required for PBS authority prescriptions. Australian rheumatology practice also faces workforce shortages and geographic access challenges, where validated CDSS tools could theoretically support general practitioners in rural and remote settings. However, Australian EHR data infrastructure and interoperability limitations would need to be addressed before deployment. The My Health Record system could theoretically serve as a data source but raises privacy and governance considerations under the Privacy Act 1988. Rheumatologists, general practitioners, and other clinicians managing patients with rheumatic diseases including rheumatoid arthritis, systemic lupus erythematosus, vasculitis, and other complex inflammatory conditions. Potentially applicable to clinical informatics teams and health system administrators evaluating CDSS procurement.
Abstract
Clinical decision support systems (CDSS) have the potential to enhance rheumatology practice by assisting with differential diagnosis, treatment decisions, and predicting patient outcomes. Rheumatic conditions are complex diseases largely diagnosed clinically rather than with a predefined set of clinical, laboratory, or imaging findings. Newer artificial intelligence (AI)-driven CDSS, known as machine-learning-based systems, may be better suited for applications to rheumatic conditions compared to knowledge-based systems, which rely on a set of predefined rules. This report reviews existing studies on CDSS in rheumatology and highlights the potential benefits and pitfalls of incorporating AI-driven CDSS into rheumatology practice.
References
- 1.Usiskin, I. M., Danila, M. I., Cai, T., & Liao, K. P. (2026). Toward artificial intelligence-driven clinical decision support tools in rheumatology. Rheumatic Disease Clinics of North America. https://doi.org/10.1016/j.rdc.2026.03.001
Related Research
The Journal of rheumatology
Examining the Role of Wearables in Inflammatory Arthritis Care: A Narrative Literature Review
3 Aug 2026
Rheumatic diseases clinics of North America
Demystifying Artificial Intelligence: Key Concepts with Examples in Rheumatology
2 Aug 2026
Rheumatic diseases clinics of North America
Machine Learning-Enhanced Autoantibody Discovery and Diagnostics in Systemic Autoimmune Rheumatic Diseases
2 Aug 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service